New drug HWK-016 takes aim at Hard-to-Treat cancers

NCT ID NCT07470853

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals are to find the safest dose and to understand side effects. About 265 adults will take part, and some will also receive a second drug called bevacizumab.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atrium Health - Wake Forest

    NOT_YET_RECRUITING

    Charlotte, North Carolina, 282204, United States

  • Karmanos Cancer Center

    NOT_YET_RECRUITING

    Detroit, Michigan, 48201, United States

  • Memorial Sloan Kettering Cancer Center

    NOT_YET_RECRUITING

    New York, New York, 07920, United States

  • Ohio State University Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • SCRI - Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • SCRI - Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75230, United States

  • SCRI - Sydney Kimmel Cancer Center - Jefferson Health

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • START - Los Angeles

    RECRUITING

    Los Angeles, California, 90025, United States

  • START Mountain

    RECRUITING

    Salt Lake City, Utah, 84119, United States

  • St. Francis Medical Center (OSF Healthcare)

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Start - Ny

    RECRUITING

    Lake Success, New York, 11042, United States

  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute

    RECRUITING

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.